title: Epoprostenol (also known as Prostacycin or Prostaglandin I2 (PGI2))
text: |
  Epoprostenol (also known as Prostacycin or Prostaglandin I2 (PGI2))
  |
  bet | 189/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Epoprostenol (also known as Prostacycin or Prostaglandin I2 (PGI2))
  Revision Date : 27/04/2021
  |
  Approved : TCO, KOH
  |
  Indication :
  |
  Persistent pulmonary hypertension of the newborn unresponsive to usual ventilatory strategies, inhaled nitric oxide and appropriate inotropic support.
  |
  Dose :
  |
  Initial dose 2nanograms/kg/minute
  Titrate to clinical effect increasing by 1-2nanogram/kg/min not faster than every 15 minutes.
  Limited evidence for max dose for PPHN in neonates (UK guidance (BNF/NICE) state usual max 20nanograms/kg/min; rarely up to 40nanograms/kg/min)
  Doses up to 80-150nanograms/kg/min used in adult and paediatric patients for chronic pulmonary arterial hypertension
  |
  Interval :
  |
  Continuous infusion only
  |
  Route :
  |
  I.V. (central venous line strongly recommended)
  |
  Total Daily Dose :
  |
  |
  Comments :
  |
  |
  |
  | |